title: Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
abstract: OBJECTIVE
  We re-evaluated the clinical, histopathological and immunohistochemical features of neuroendocrine tumors (NETs) diagnosed in our pathology laboratory between 2004 and 2012 and re-classified them according to the WHO-2000 and WHO-2010 criteria.
  
  
  METHODS
  The study included NET samples of 106 patients having gastroenteropancreatic and hepatobiliary tumors. The histopathological findings were re-assessed. The cases were re-appraised based on the WHO-2000 and WHO-2010 criteria. The association between survival and Ki-67 index was analysed.
  
  
  RESULTS
  The most frequent localization was the stomach. The average tumor size was 3.0±4.1 cm. Differentiation was poor in 17 cases (16.0%). Lymphovascular invasion was detected in 16.1% (n = 17) and necrosis was identified in 15.1% (n = 16). The average number of Ki-67 was 9.1±19.9. Ki-67 measurements were significantly higher in patients who died compared to those who survived (p <0.01). In ROC analysis, the cut-off point for Ki-67 was 5.
  
  
  CONCLUSIONS
  Our study is a single-center study comprising patients from Turkey for a period of 8 years. We found that the most frequent localization is the stomach. This ratio is associated with common use of endoscopy in our center. The specimens were re-evaluated according to the WHO-2000 and WHO-2010 classification systems the data and terminology have been updated.
authors.forename: Selvinaz
authors.initials: S
authors.lastname: Ozkara
authors.forename: Fugen
authors.initials: F
authors.lastname: Aker
authors.forename: Atakan
authors.initials: A
authors.lastname: Yesil
authors.forename: Ebubekir
authors.initials: E
authors.lastname: Senates
authors.forename: Ceren
authors.initials: C
authors.lastname: Canbey
authors.forename: Ali
authors.initials: A
authors.lastname: Yitik
authors.forename: Can
authors.initials: C
authors.lastname: Gonen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D002454:Cell Differentiation; D049109:Cell Proliferation; D053379:Chromogranin A / Q000032:analysis; D016099:Endoscopy, Gastrointestinal; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007414:Intestinal Neoplasms / Q000737:chemistry / Q000145:classification / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000737:chemistry / Q000145:classification / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000145:classification / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D011237:Predictive Value of Tests; D012372:ROC Curve; D013274:Stomach Neoplasms / Q000737:chemistry / Q000145:classification / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D016019:Survival Analysis; D016708:Synaptophysin / Q000032:analysis; D009626:Terminology as Topic; D013997:Time Factors; D047368:Tumor Burden; D014421:Turkey; D014944:World Health Organization; D055815:Young Adult
chemical_list: C506150:CHGA protein, human; D053379:Chromogranin A; D019394:Ki-67 Antigen; C569014:SYP protein, human; D016708:Synaptophysin